

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

24.89

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 958 833 A1

(12) EUROPEAN PATENT APPLICATION

(43) Date of publication: 24.11.1999 Bulletin 1999/47
(51) Int. Cl.⁶: A61K 38/55, A61K 38/56, A61L 15/44, G01N 33/50
(21) Application number: 98201694.1
(22) Date of filing: 20.05.1998

<p>(84) Designated Contracting States: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE Designated Extension States: AL LT LV MK RO SI</p> <p>(71) Applicant: Erasmus Universiteit Rotterdam 3015 GE Rotterdam (NL)</p>	<p>(72) Inventor: The designation of the inventor has not yet been filed</p> <p>(74) Representative: Smulders, Theodorus A.H.J., Ir. et al Vereenigde Octroolbureaux Nieuwe Parklaan 97 2587 BN 's-Gravenhage (NL)</p>
---	--

(54) Methods and means for preventing or treating inflammation

(57) The invention relates to methods and means for preventing, treating or reducing inflammation by inhibiting proteolytic activity, more specifically for preventing or reducing inflammations of skin or intestine. The invention provides a method for reducing or preventing an inflammation comprising subjecting a mammal to a treatment with at least one inhibitor which is capable of inhibiting proteolytic activity. In a preferred embodiment of the invention, said inhibitor is a plant product, such as potato juice or an inhibitor derived thereof.

EP 0 958 833 A1

Description

[0001] The invention relates to methods and means for preventing, treating or reducing inflammation by inhibiting proteolytic activity, more specifically for preventing or reducing inflammations of skin or intestine.

5 [0002] Inflammations of skin (dermatitis) or intestine (enteritis) are of various origin. Initially, allergic reactions, infections with (pathogenic) micro-organisms, excoriation by chemical or physical means, and other causes are instrumental in causing an inflammation. These causal events are immediately followed by the so necessary reaction of the body, resulting in an interplay of actions and events aiming at restoration of the skin or intestine in its original state. In this interplay of cause-and effect, various activities of proteolytic enzymes are seen. Granulocytes, mast-cells, macro-
10 phages and other immediate actors in inflammatory responses and attracted by cytokines to a site of inflammation, contain (and secrete) proteases, such as chymotryptic protease and elastase, that act as mediators or are instrumental in cleaving and removing proteins derived from pathogens or from the surrounding degenerated tissue. Bacteria, either as primary causal agent, or during a secondary infection, and other (pathogenic) micro-organisms, secrete proteases that damage the surrounding tissue for their purposes. In this battlefield between host and invader, excess proteolytic
15 reactions are kept at bay by, often very specific, protease inhibitors. Well known are proteinase/proteinase inhibitor systems such as PMN-elastase/alpha-1-proteinase inhibitor and cathepsin G/alpha-1-antichymotrypsin.

[0003] Proteolytic enzymes in themselves, however, can also be a cause of inflammation. This is especially the case for digestive enzymes, which are found in the intestinal tract. In order to degrade dietary protein, the stomach, the pancreas and the small intestinal brush border secrete several kinds of proteases. Pepsin from the stomach works optimal
20 at pH 2, pancreatic and brush border enzymes, such as trypsin, chymotrypsin and elastase work optimal at pH 7-8. In adults, the small intestine has a length of seven meters and the transit time of its contents is about 3 hours; this part of the intestine is colonised by only a few bacteria but is filled with a watery mixture of food and a wide array and large quantities of digestive enzymes, such as lipases and proteases. However, in the large intestine (colon and caecum) the water content is greatly reduced, and the activity of the enzymes is neutralised by i.e. bacteria. Neutralised and digested
25 remnants of food and bacteria (faeces) finally leave the body via the rectum. Only when the colon cannot effectively reduce the water content and neutralise the enzymes, the faeces may still contain proteolytic activity, which, during periods of diarrhoea or faecal incontinence, may be very irritating to intra-anal and perineal skin.

[0004] The skin, especially of humans, is, although it is protected by the stratum corneum which consists mainly of keratine, as any other proteinaceous substance, very susceptible to the proteolytic action of proteases, consequently
30 fluid like small intestinal content may cause severe inflammation.

[0005] In babies and infants, the intestine is much less well developed, especially the colon functions different from that in adults. This is the reason why digestive enzymes in faeces of babies and infants are not neutralized; the contents of faeces resemble more the contents of the small intestine, albeit having passed the colon. Therefore, perineal (peri-anal) dermatitis is more often found with babies or infants than with adults. Also, (hospitalised) infants and children with
35 gastro-intestinal disorders are prone to such a dermatitis. Such a dermatitis, defined by skin erythema, vesiculas, wetness, oedema and disruption (excoriation) of perineal skin, is also found with diaper rash, and can manifest itself in rather mild to very severe forms. With diaper rash, complicating factors are the accumulation of urine, whereby ureum is converted by faecal bacteria to ammonia, thereby raising the pH to an even better value for the activity of proteolytic enzymes. Since the skin is extremely susceptible to infections, care should be taken to prevent such inflammations
40 related to (faecal) proteolytic activity.

[0006] Yet other cases of dermatitis are found with patients that have undergone resections of colon and/or ileum a stoma. Pouchitis, an intestinal inflammation, is a major complication of ileoanal anastomosis with reservoir construction after colon resection and is characterised by clinical symptoms and inflammation of the reservoir (pouch). Peristomal (circumstomal) dermatitis is found with those patients that have been provided with an ileostoma that opens up at the
45 surface of the abdomen, ending in an artificial reservoir that needs to be emptied daily. In inflammatory bowel diseases (IBD, such as Crohn's disease (CD), ulcerative colitis (UC) and pouchitis), and inflammation with an unknown aetiology, the role of the intestinal flora and pathogens, proteolytic enzymes derived from these micro-organisms and endogenous (e.g. pancreatic or leukocyte/granulocyte) proteolytic enzymes and their contribution to degradation of protecting mucoglycoproteins and the underlying tissues is not understood.

50 [0007] Especially in above cases where the colon is removed or its function is affected or immature, it is evident that the proteolytic activity is still very high when the faeces is excreted, leading to various degrees of perineal dermatitis.

[0008] It goes without saying that many medications and personal care items have been developed in order to remedy the often painful consequences of above discussed inflammations. General anti-inflammatory therapy often resorts to treatment with corticosteroids, despite the serious side-effects that are often seen with these medicaments. Other ways
55 of treating are mainly based on providing either a protective layer to the skin, e.g by applying a lipid-based ointment, containing additives such as zinc, or by frequently cleaning an area at risk. Special personal care items have been developed, varying from specific wet wipes for perineal care, diapers that stay very dry despite heavy soiling by the child or patient, to products (stoma care appliances), such as adhesive and absorbing discs and stoma rinsing fluid, that are

specifically designed for stoma care with patients with ileostomy or ileo-anal anastomosis.

[0009] However, none of these treatments can really do no more than alleviate one or more of above and below described clinical symptoms.

[0010] The invention provides a method for treating, reducing or preventing an inflammation comprising subjecting a mammal to a treatment with at least one inhibitor which is capable of inhibiting proteolytic activity. The invention is applicable to human and veterinary medicine and care.

[0011] A preferred embodiment of the invention is wherein said mammal is a human being suffering from for example dermatitis. Treating for example a dermatitis with a protease inhibitor reduces the proteolytic activity of the proteases involved in the inflammation. Especially when in the interplay of causes and effects seen during inflammation, the activity of proteolytic enzymes is too high, the invention provides a method to reduce this activity (be it from host or from invader) by treatment with at least one inhibitor which is capable of inhibiting proteolytic activity.

[0012] Said treatment is provided by applying said inhibitor in an ointment, cream, gel, powder, or any other suitable form to the location of the inflammation. These substances can for example also be carried on wipes impregnated with an inhibitor, in sprays or in rinsing fluid.

[0013] In a preferred embodiment of the invention, treatment is provided for an inflammation which is intestinal, perineal or peristomal, as is for instance seen with babies or infants with diaper rash, with children or adults with diarrhoea or faecal incontinence, with patients with inflammatory bowel syndrome and with stoma patients, which all suffer from the effects of proteolytic activity which is mainly faecal.

[0014] Treatment of faecal proteolytic activity can occur by applying said inhibitor in an ointment, cream, gel, powder, or any other suitable form to the perineal or peristomal location of the inflammation. Intestinal inflammations, such as seen with IBD or pouchitis can be treated by rinsing the affected location in the digestive tract by for example administering an enema, or can be administered orally, preferably in a pharmaceutical composition, such as a draught or mixture pill, that can passage relatively unaffected through oesophagus and stomach.

[0015] These inhibitor substances can for example also be carried on wipes impregnated with an inhibitor, in sprays or in rinsing fluid. Also, it is possible to impregnate a diaper (during diaper production or shortly before use) with an inhibitor, thereby providing a method and means against diaper rash. In a preferred embodiment, such a diaper is treated or impregnated with an inhibitor as provided by the invention in at least that diaper area (and underlying parts) that has, when in use, contact with the perineum of the baby, infant, child or adult. With diapers, said contact area normally comprises the diaper surface that is in contact with the perineum.

[0016] The invention provides a method of treatment which comprises administration to the patient or mammal prone to an inflammation of an inhibitor capable of inhibiting proteolytic activity of a protease. Inhibitors of proteolytic activity are widely known. For example, acid has an inhibiting effect on the hydrolysis of proteins by pancreatic proteases and thus a pH decreasing substance can be used as an inhibitor as provided by the invention.

[0017] Also, substances such as activated charcoal (one such product is known as Norit), can act as protease inhibitor through their adsorbing properties. In the experimental part, several examples are given of a treatment provided by the invention whereby activated charcoal, for example Norit[®], is used to treat an inflammation such as for example pouchitis.

[0018] In a preferred embodiment of the invention, the invention provides methods and means capable of inhibiting proteolytic activity of a protease. Many protease inhibitors are known (see for example G. Salvesen and H. Nagase. Proteolytic enzymes, a practical approach. Eds R.J. Beynon and J.S. Bond In: The practical approach series. 1989). Although non-specific inhibitors are known (i.e. human plasma α -macroglobulin), most discriminate between protease classes or even subclasses. Substances such as peptide aldehydes or peptide chloromethyl ketones are very specific for subclasses of proteases (proteinases), depending on the peptide sequence they mimic. Others, such as metal chelators act only against metallo-proteinases or calcium dependent proteinases. Class-specific inhibitors are found against serine proteinase, against cysteine proteinase, against aspartic proteinase, and so on. These protease inhibitors are often commercially available as purified substances for use in biochemical preparations and may be expensive.

[0019] A preferred method according to the invention is a method wherein an inhibitor is derived from a plant, i.e. said inhibitor is a plant product comprising protease inhibiting activity. As an example, such a product derived of a plant is activated charcoal, which is obtained by burning peat or wood. A much preferred method according to the invention is a method wherein an inhibitor is derived from a plant that can give rise to fruit, seed, tubers or roots. Such plants often protect their fruits, seeds, tubers or roots against pests by inclusion of potent protease inhibitors and mixtures thereof in those fruits, seeds, tubers or roots. For example, cereals and legumes, such as wheat or soy beans, contain protease inhibitors such as soy bean trypsin inhibitor (SBTI), which generally has activity against trypsin or chymotrypsin but not against other proteinase classes. Tubers and roots, such as potato and cassave, but also yam, beets and sweetroot, and others, contain potent inhibitors of a wide variety of digestive tract proteases such as aminopeptidases, carboxypeptidases, chymotrypsin, trypsin and elastase. Potato tubers are an extraordinarily rich source of a variety of inhibitors of all major intestinal digestive endo- and exoproteinase of animals (Pearce et al., Arch. Biochem. Biophys, 213, 456-462, 1982). Such inhibitors act as anti-nutrients that are present as part of the natural chemical defense mecha-

nisms of plants such as tubers and roots against attacking pests. In potatoes, major inhibitors are polypeptide trypsin inhibitor (PTI), polypeptide chymotrypsin inhibitor I and II (PCI-I and PCI-II), inhibitor II against chymotrypsin and trypsin, and carboxypeptidase inhibitor, which all have analogues in other plants. These act alone and in concert against the major animal digestive proteinases.

5 [0020] The invention provides the use of an inhibitor or plant product or extract capable of inhibiting proteolytic activity for preparing a pharmaceutical or personal care composition for reducing or preventing an inflammation. In the experimental part an example is given of such a product which comprises potato juice or an inhibitor derived thereof, for example by freeze-drying. Such a composition can comprise an ointment, cream, gel, powder, or any other suitable form in which an inhibitor can be applied to a patient. In a preferred embodiment of the invention, the invention provides
10 the use of an inhibitor or plant product capable of inhibiting proteolytic activity for preparing a composition for reducing or preventing an inflammation which is an intestinal, perineal or peristomal inflammation. Such a composition can be in the form of a rinsing fluid, can be contained in capsules that passage through oesophagus and stomach, can be in (pre-fabricated) wipes or diapers, wherein the inhibitor (or plant product) is added during production or shortly before use. In a preferred embodiment the invention provides the use of an inhibitor capable of inhibiting proteolytic activity for preparing
15 a personal or medical care composition for perineal (perianal) and/or peristomal care, for example to counter proteolytic activity that is faecal.

[0021] For example, it is possible to prevent perineal dermatitis by rinsing the reservoir and the perineal skin with a protease inhibitor containing fluid or a protecting ointment with protease inhibitors. Also, it is possible to pre-treat diapers or personal care compositions that adsorb soiling with inhibitor powder.

20 [0022] The invention provides the use of an inhibitor or plant product capable of inhibiting proteolytic activity for preparing a pharmaceutical or personal care composition wherein said inhibitor or product is derived from a plant, preferably wherein said plant can give rise to fruit, seed, tubers or roots, such as a potato plant. Such an inhibitor (product, composition or mixture), as explained above, is active against a protease which is selected from the group of pancreatic and granulocyte proteases. In a particular embodiment of the invention said inhibitor (composition or mixture) is capable
25 of inhibiting papain and/or pronase, illustrating its broad spectrum and effectivity.

[0023] The invention also provides a personal care composition, rinsing fluids, wetties, powder, ointments, for perianal and/or peri-stomal care or a diaper comprising an inhibitor of proteolytic activity. The invention furthermore provides a protease inhibitor for use in a method according to the invention. Attention to skin care can already begin at the time of surgery, for example inhibitor containing rinse fluid. Inhibitors may be incorporated in stoma appliances, such as
30 adhesive and absorbing discs and in stoma rinsing fluids and ointments.

[0024] Also, the invention provides a skin test for studying the effect of a protease inhibitor on proteolytic activity or inflammatory action of a substance, preferably of faeces.

[0025] The invention is further described in the experimental part which is not limiting the invention.

35 Experimental part

[0026] In adults, the small intestine has a length of seven meters and the transit time of its contents is about 3 hours; this is the reason why this part of the intestine is colonised by only a few bacteria, when compared to the large intestine. However the colon is colonized by large numbers of bacteria (10^{10} - 10^{11} /gram). The transit is slow (24 hours) and the
40 main function of the colon is absorption of water.

[0027] Finally, faeces consists of one part solids and two parts of water. Half of the dry material are bacteria; the remnants are largely dietary fibre and host-derived material such as shed epithelial cells and mucus. The most active site of bacterial fermentation is the place where the contents of the ileum reaches the caecum. Abundant nutrients are available, the percentage water is high and the flora has optimal conditions to multiply. Few data about this part of the
45 (human) intestine are known, but the pH, measured in sudden death victims, is very low (pH 4.5-5.5).

[0028] The colon flora consist for 99.9% of obligate anaerobic bacteria; anaerobic-facultative aerobic bacteria such as coliforms are a minority (about 10^4 - 10^7 bacteria/gram faeces). The anaerobic colon flora is very stable and it is nearly impossible to induce alterations at species or genus level, even by drastic changes in diet (antibiotics or infection with enteropathogens however might disturb the resident flora). One of the causes of this phenomenon is that the most
50 important nutrients derive from endogenous material, digestive fluids, mucus, etc. A part of the digestive proteins (also the bile acids) are reabsorbed from the distal part of the ileum, the remainder is converted or digested in the colon. The colonflora is thought to play an important role in the inactivation of digestive pancreatic enzymes such as proteases.

[0029] In babies and infants, the intestine is much less well developed, especially the colon does not function as well as in adults. This is the reason why digestive enzymes in faeces of babies and infants are not neutralized and/or reabsorbed; its contents resemble more the contents of the small intestine, including a high proteolytic activity albeit having
55 passed the colon.

[0030] The principal endogenous nutrient sources are probably glycoproteins from gastric and intestinal mucus which contains up to 90% carbohydrate. Bacterial glycosidases degrade the oligosaccharide side chains which protect the

glycoprotein from proteolytic destruction. When the protein core lacks the protection of the carbohydrates it is no longer resistant to proteolysis by pancreatic (and bacterial) proteases. In the healthy colon there is a balance between the production and the degradation of mucus.

5 [0031] Much attention has been paid to inflammatory bowel diseases (IBD): Crohn's disease (CD), ulcerative colitis (UC) and pouchitis. Pouchitis is a major complication of ileoanal anastomosis with reservoir construction, after colonresection for UC and is characterized by clinical symptoms and inflammation of the reservoir (pouch). The role of the intestinal flora in IBD was investigated concerning pathogens and their contribution to degradation of the protecting mucusglycoproteins.

10 [0032] Patients with inflammations in the gut show a loss of the integrity of the mucosa. We have studied the potential harmful role of bacterial glycosidases and bacterial and host-derived proteases by degrading mucus glycoproteins. Therefore in patients with IBD the composition of the intestinal flora and the activity of glycosidases and proteases was estimated. Also enzymatic activity was measured in germ-free rats to establish the influence of the flora.

15 [0033] These studies showed that faeces of patients with active CD, patients with an ileostomy and patients with a pouch have a high proteolytic activity. Proteases enter the duodenum largely as secretions from the liver, brush-border and pancreas. A part of the activity is lost in the terminal ileum, probably due to absorption and/or action of endogenous inhibitors. In faeces of healthy subjects only a very low or no enzyme activity at all, was estimated, which is probably largely of bacterial origin. However germ-free animals such as rats show a high proteolytic activity throughout the whole large intestine. Patients with active IBD, ileostomy patients and patients with a pouch were found to have a high faecal proteolytic activity. From this we may conclude that a complete colonflora and a normal (slow) transit is necessary to inactivate these enzymes.

20 [0034] The high proteolytic activity in faeces of patients with IBD may cause an increased degradation of mucus glycoproteins and may play a role in the maintenance of the inflammation of the mucosa. In vitro experiments confirmed this hypothesis. The idea was born to treat patients such as those with an ileoanal anastomosis (IAA) with protease-inhibitors to prevent perineal dermatitis. Patients who are operated for UC or familial adenomatous polyposis (FAP), are considered for construction of an ileal reservoir after colon resection. This small reservoir is connected with the anus. The period after the operation is a hard time for most of the patients. Short after the operation the patients faeces has a watery consistence, the patients are often not (yet) continent and this results in irritation of the perineal skin (perineal dermatitis). The major cause of perineal dermatitis is the degradation of the epidermis (which consists largely of the protein keratin) by proteases.

30 [0035] Proteolytic activity was measured in faeces of these patients and was found to be very high. Furthermore, 75% of the patients developed a moderate to severe perineal dermatitis; 25% did not have any sign of irritation.

Materials and methods

35 *Proteolytic activity/subjects*

[0036] Faecal samples from twenty-seven patients with Crohn's disease (CD) were studied. Twelve patients, aged 27-58 years, had undergone intestinal surgery 3-12 years previously; locations of the resections were terminal ileum, ileum and caecum, and colon. A second group of patients was not operated; the principal sites of inflammation were ileum, 40 ileum and colon, and colon. The diagnosis CD was established with the usual clinical, radiological and histopathological criteria. All patients were outpatients.

[0037] Twelve healthy volunteers, aged 23-48 years were examined for comparison.

45 [0038] Ileostomy effluents were obtained from five adult patients with a conventional ileostomy (aged 38-71 years). They had undergone total colectomy more than five years before, for relief of CD or ulcerative colitis (UC), and were all currently in good health.

50 [0039] Fourteen patients with a pouch (median age 27 years) were studied. The patients had a restorative proctocolectomy for UC or familial adenomatous polyposis. An S pouch was constructed in 12 patients, whereas in two patients a W pouch was created. This study was performed at least one year after the restorative colectomy. The diagnosis pouchitis was based on clinical symptoms, endoscopic features of acute non-specific inflammation and histological evidence of an inflammatory cell infiltrate. Using these criteria five patients presented pouchitis and nine did not (controls).

[0040] Faecal samples from thirteen patients operated for the construction of a reservoir with ileoanal anastomosis (IAA) were collected within 14 days after the operation.

55 *Proteolytic activity/laboratory animals*

[0041] Faeces from 4 conventional (Wistar) and 4 germ-free rats (Wag/Rij) were studied. From 2 conventional and 2 germ-free rats the contents of the intestinal tract were studied.

[0042] Faecal samples from 20 colectomized dogs, purebred Beagles (Harlan) were collected. Three ileostomy groups were studied. In ten dogs a standard Brooke ileostomy was constructed by subtotal colectomy. In five dogs a valveless ileal reservoir (pouch) was fashioned by a side-to-side isoantiperistaltic anastomosis. After a recovery period of 2 weeks a schedule of increasing periods of occlusion was started, except for 5 dogs. The maximum tolerable occlusion time was 2.5-3 h for the ileostomy group and 4-7 h for the reservoir group. In five dogs a continent ileostomy (Kock's pouch) was constructed, which was emptied 2-5 times per 24 hours by catheterization.

Proteolytic activity/faecal samples and intestinal contents

[0043] Faeces was frozen and stored at -20°C within 3 h of passage. Preliminary studies showed no changes in proteolytic activity during at least 4 months of storage. Samples of 1 g were transferred to 24 vol of 0.1 M phosphate buffer pH 7.6 and homogenized ('Stomacher', Lab blender 400). Coarse particles were removed from the homogenates by gauze filtration (Utermohlen, refolded to 2 layers); these samples are further referred to as 'faecal homogenates'.

[0044] Immediately after killing the rats the whole intestine was removed and prepared. The small intestine was divided into 4 parts of equal length and the contents of each part was carefully washed with 0.1 M phosphate buffer (pH 7.2). Samples from coecum and colon were treated in the same way as faeces.

Proteolytic activity/enzyme assay

[0045] Proteolytic activity was determined in the faecal homogenates in appropriate dilutions (up to 250-fold) in 0.1 M phosphate buffer (pH 7.6). Penicilline (0.1% w/v) was added to prevent bacterial growth. In the more recent inhibition tests no penicillin was used. Samples of 0.1 ml were incubated with 0.1 ml 1% (w/v) azocasein (Sigma) in phosphate buffer at 37°C during 1 h. The reaction was stopped by addition of 0.2 ml 10% (w/v) trichloroacetic acid (TCA); after 10 mm at room temperature unhydrolysed azocasein, bacteria and other particles were removed by centrifugation at 10,000 rpm during 10 mm. Then 0.1 ml of the clear supernatant was transferred to 0.1 ml of 1 N NaOH in flatbottom 24 wells microplates. To the blank assays azocasein was added after incubation an addition of TCA. The absorption of the samples was measured at 450 nm and compared with standard curves obtained from solutions of azocasein. Proteolytic activity was expressed as milligrams azocasein hydrolysed during 1 h per gram dry or wet weight of sample. Each diluted sample was tested for other than enzymatic substrate hydrolysis after heating at 80°C for 10 mm. Spontaneous substrate hydrolysis was tested by incubation of the substrate with buffer.

Proteolytic activity/effect of pH

[0046] To test the effect of pH on the proteolytic activity the faecal samples were diluted in citric acid-phosphate buffer (0.1 M Na₂HPO₄/2H₂O, 0.1 M citric acid/H₂O) pH 5.2, 5.8, 6.8 and 7.6. Additionally the substrate solutions were made in appropriate buffers.

Proteolytic activity/protease inhibitors

[0047] The following inhibitors were used:

- Trasylol (Aprotinin) (Bayer) not diluted
- Ovomucoid () 1 % (w/v) in 0.1 M phosphate buffer pH 7.6
- Foetal Calf Serum (FCS) () not diluted
- Trypsin inhibitor II-from Soybean (STI) (T-9003; Sigma) 1% (w/v) in phosphate buffer pH 7.6
- Norit A (supra USP, 951191), B (Test EUR, A6910), E (Supra USP, 940260), PRSH, Carbomix, tablets
- Premium powder (Hollister)
- Potato juice (PJ) from "Bintjes", prepared by separating the pulp from the fluid by filtration through paper, centrifugation by 13,000 rpm for 30 mm, filtration through 0.45 micron filter and freeze-drying. Ten gram PJ-powder was derived of about 200 ml fluid. This crude product contained about 25 % protein.

[0048] In general, protease inhibitors which are present in potatoes for example can be recovered by grinding potatoes, removing starch and other solids, and for example freeze-drying the juice. The purity of the protease inhibitor preparation can be improved by removing non-proteinaceous material and/or low molecular weight peptides and/or amino acids present in potato juice by e.g. centrifugation, microfiltration, ultrafiltration, diafiltration or electrodialysis. Furthermore, protein can be selectively recovered in a relatively crude form from the potato juice matrix. This can be achieved by e.g. ultrafiltration, iso-electric precipitation, (co)floculation with polyelectrolytes or any other flocculation aid, coprecipitation with other proteins, protein precipitation with salt (salting out), or by

changing the quality of the solvent e.g. by adding acetone, methanol, ethanol or iso-propyl-alcohol, by iso-electric precipitation and thermal fractionation and other techniques known to anyone skilled in the art. Since protease inhibitors in potato juice are relatively heat stable, a moderate thermal treatment leads to denaturation and coagulation of less stable proteins. Coagulated protein can subsequently be removed by techniques as simple as e.g. centrifugation. Although
 5 some protease-inhibiting activity is lost, the purity of the remaining protease inhibitors is increased. Even further purification is possible by ultrafiltration or by salting out the protease inhibitors, and subsequent removal of salt and other undesired components by ultra- and diafiltration. Alternatively, isolation of several protease inhibitors is possible by affinity chromatography, either directly from the crude potato juice matrix or after pre-purification.

[0049] In most of the experiments the inhibitor was added to faeces (diluted 1:25 in buffer), mixed for 5-15 min and
 10 added to the substrate; PJ-powder was added to undiluted faeces (1:1) and after mixing, diluted (1:25) with buffer. In each experiment controls were assayed (sterilized faeces, sterilized inhibitors, buffer solutions).

Proteolytic activity/purified enzymes

15 [0050] The following enzymes were tested in the inhibition experiments:

- bovine pancreatic trypsin (Serva)
 - bovine pancreatic α -chymotrypsin (Merck, Sigma)
 - bovine pancreatic elastase (Sigma)
 - 20 - papaine (Sigma)
 - pronase (Sigma)
- (carboxypeptidase and leucinaminopeptidase were tested, but did not hydrolyze azocasein)

[0051] All enzymes were used in a concentration of 0.2 % (w/v) in buffer.

Proteolytic activity/skin tests

[0052] Skin tests were performed on the ventral part of the fore-arm. The following solutions were tested: 1. supernatant from faeces of a patient with an ileum reservoir with a high proteolytic activity; 2. the same supernatant, but steri-
 30 lised; 3. supernatant with 0.25% STI (w/v) and 4. 0.25% STI in buffer. Two hundred μ l of each solution were placed on folded cambric on the skin and covered with plastic and adhesion wound pad. Total incubation time was 7 h, but after 3 and 5 h 100 μ l buffer was added to each of the test patches to prevent dehydration.

Inhibition of faecal proteolytic activity by products from Potato Juice Euro 1, Euro 2, Euro 3

Materials and methods

Faecal samples

40 [0053] Faeces from 1 patient with an ileostomy, 1 patient with a good-functioning pouch, 1 patient 14 days after colectomy and the construction of a pouch, 2 babies aged 4 months were used.

[0054] Faeces were used undiluted except for the babies, which was diluted 1:1 in phosphate buffer pH 7.6 and centrifuged 10 min at 10,000 g.

EURO's

[0055] EURO's were used as 1:5, 1:10, 1:25, 1:50 and 1:100 dilutions in phosphate buffer pH 7.6.

[0056] Faeces and EURO were mixed 1:1 for 10 minutes, then the mixture was diluted in phosphate buffer pH 7.6 1:12.5.

50 [0057] In both dilutions proteolytic activity was measured with azocaseine as substrate.

Skin tests

[0058] Patch Test Chambers (van der Bend) of 10 by 10 mm, filled with 50 μ l of a test solution were placed on the skin
 55 of the upper part of the back of 2 healthy subjects and fixed with Fixomull Stretch self adhesive tape; the distance between them was 15 mm. One series of 4 test chambers was placed from cranial to caudal, a second series from caudal to cranial.

[0059] The test solutions had the following composition:

A. elastase, trypsin and α -chymotrypsin, end concentration of each of the enzymes 1% (Enzyme Mix) soluted in sterilized faecal supernatant from an ileostomy patient (FS)

B. FS

C. Euro 2 (end concentration 5%) soluted in FS with Enzyme Mix

D. Euro 2 in FS

[0060] After 24 hours the test chambers were removed and the skin was rinsed with tap water. Sites were inspected for erythema and dermatitis after 1, 2, 4, 6 and 24 hours.

Results

1 Proteolytic activity in faeces

[0061] Proteolytic activity in faeces from healthy subjects was low. However Table 1 shows that patients with CD, ileostomy patients and patients with a pouch (with and without pouchitis) have a high proteolytic activity.

Table 1

Proteolytic activity in faeces of healthy subjects and patients				
Proteolytic activity	Dry weight of faeces mg/g			
	median	(range)	median	(range)
Healthy subjects	17.9*	(7.5-44.0)	313	(164-403)
Patients with CD				
- no resections	47.9	(19.1-192.0)	216	(128-228)
- resections	228.7	(130.6-356.6)	134	(84-175)
Patients with ileostomy	336	(89-972)	88	(69-120)
Patients with a pouch				
- no pouchitis				
- pouchitis	14**	(5.5-23.5)	83	(57-103)
	14	(7.1-17.3)	52	30-110)
Patients with IAA	53	(18-105)	ND	(<30)

* azocasein hydrolyzed, mg/h/g dry faeces

** azocasein hydrolyzed, mg/h/g wet faeces

[0062] Comparable results were found in faecal samples of laboratory animals. Faeces from normal dogs and rats had a very low proteolytic activity. Proteolytic activity was found to be high in ileostomy output and in valveless pouches of dogs despite occlusion; however continent pouches showed a complete normalization concerning the proteolytic activity (and several other parameters which are not discussed in this context). In contrast with germ-free rats in the colon of conventional animals, the proteolytic activity is strongly decreased, which suggests a role for the colon flora in inactivation (and/or degradation) of digestive proteases. In infants, proteolytic activity varies with age. An estimate of the proteolytic activity in faeces of healthy infant and children show in infants (n=10, 4-12 months) very high activity, in children (n=9, 1-2 years) lower, but still high activity and in children (n=12, 2-8 years) decreasing activity.

[0063] In a further experiment, the proteolytic activity in faeces of 31 children was again found to decrease with age, in children of 4 months (n=4): 191 mg hydrolyzed azocasein/h/g faeces, in children of 6 months (n=2): 109 mg, in a child of 8 months (n=1): 118 mg, in children of 11 months (n=3): 105 mg, in children of 16 months (n=3): 73 mg, in children of 24 months (n=6): 34 mg, in children of 3 years (n=5): 24 mg, in children of 5 years (n=3): 3 mg, in children of 7 years (n=4): 14 mg was found.

2 Inhibition of proteolytic activity

pH

- 5 [0064] Figure 3 shows that the pH dependence of the proteolytic activity was similar in each of the tested samples. At pH 6.8 and 7.6 the activities were respectively three and four times higher than at pH 5.2 ($p < 0.001$ for both comparisons). This means that at pH of 5.2 the proteolytic activity is inhibited for 75%.

STI

- 10 [0065] The next table (Table 2) shows the results of our first experiments with protease inhibitors. Conditions of the assays were different but Trasylol, ovomucoid and FCS had effects on the proteolytic activity which were less promising or (conflicting) than STI. In a concentration of 1% (w/v) the inhibition was more than 80%.

Table 2.

Inhibition of proteolytic activity in patients and dogs						
	% inhibition of the proteolytic activity					
	CD patients*		Ileostomy dog		pouch dog	
	n=4	n=1*	n=3°	n=1†	n=2*	n=1**
ovomucoid	68	93	84	52		
trasyolol			54	56		16
STI 1% (0.25, 0.5, 0.75%)		93	84 (63, 61, 45)			
FCS940		94	0			
ovomucoid + trasylol			51			
ovo+tras+STI				76		
ovo+STI			70			
norit A				50		

* inhibitor added to faeces 1:2000 diluted; 20h incubated with substrate

° inhibitor added to faeces diluted 1:100; 2 h incubated

† undiluted faeces+ inhibitor (3+1), mixing for 2 h, then diluted 1:100

* undiluted faeces +norit (4+1) mixing for 2h (or 13 min), then diluted 1:100

** 2 g faeces+ 0.5 ml trasylol; mixing for 15 min, then diluted

Norit

- 40 [0066] Several kinds of norit were tested with faeces from pouch patients with a high proteolytic activity for optimal adsorbing qualities, to be used as protease inhibitor in fluid to rinse IAA patients after their operation. In this experiment
 45 Premium powder was tested also. Table 3 shows that the adsorbing capacities of norit PRSH and norit E for proteases were extremely strong.

Table 3

Effect of norit on proteolytic activity in faeces	
	% inhibition of the proteolytic activity*
Carbomix	0
Norit A (Serva)	83
Norit A	83
Norit B	0
Norit E	97
norit PRSH	100
norit tablets	58
premium powder	17

* faeces from 7 patients was diluted 1:25 with buffer with 5% norit; before addition of substrate the mixture was centrifuged (norit also may adsorb the substrate); values are medians.

[0067] Inhibition of the proteolytic activity by norit was confirmed by using skimmed milk plates; the caseine in the agar is hydrolyzed by proteases and clarification is seen after treatment with TCA.

[0068] Norit PRSH was tested in different concentrations at pH 5.2 and 7.6.

Table 4

Effect of Norit PRSH on proteolytic activity in faeces			
		% Inhibition of the proteolytic activity	
		pH 5.2	ph 7.6
Norit PRSH	1%	76	36
	2%	95	92
	3-5%	100	100

Potato Juice (PJ)

[0069] PJ was initially prepared and tested as fluid; later on a freeze-dried product was prepared. The initial end concentration of the PJ powder in the faecal suspensions was 17%. Table 5 shows the inhibition of faecal proteolytic activity by PJ and PJ powder.

Table 5

Effect of PJ on proteolytic activity of faeces				
	% Inhibition of the Proteolytic activity			
Number of patients	4*	4°	7†	7*
PJ				
- undiluted	93	(50)		
- 1:5 diluted	90			
- 1:10 diluted	51			
- 1:25 diluted	23			
PJ powder				
- 17%(w/v)			88	97
- 10%			78	90
- 5%			53	74
- 2%			20	44

* faeces 1:12.5 diluted in buffer, then mixed with Pj(1+1)

° faeces and PJ 1:1 mixed for 15 min, centrifuged, 1:25 diluted

† faeces and PJ powder (1 g in 2 ml buffer) 1:1; this gives an end concentration of 17%; no further dilutions for the assay

* same experiment as †, but the mixture was diluted 1:25 for the assay

[0070] Heating of the PJ powder in a solution of 1 g in 4 ml buffer (end concentration in faeces 5%) did decrease the inhibitor capacities as follows:

unheated PJ:	65% inhibition of the proteolytic activity
30 min at 55°C:	64%
30 min at 80°C:	47%
30 min at 90°C:	24%
30 min at 100°C:	14%

[0071] Effect of protease inhibitors on the activity of pure enzymes is shown in Table 6. PJ powder is a very potent inhibitor of several pancreatic enzymes, papain and pronase.

Table 6

Effect of protease inhibitors on purified enzymes % Inhibition of the proteolytic activity					
	trypsin	chymotrypsin	elastase	pronase	papain
STI (0.125%)	99	99	15		
- STI-A	100	80	50	0	0
- STI-B	100	100	60	0	0
- STI-C	100	100	55	0	0
Trasylol (undil.)	95	95	10		
PJ*	100	100	100	38	83
PJ (30 min at 80°C)					
- 1:5			100		
- 1:10	100	100	97		
- 1:30			95		
- 1:40			94		
- 1:50			91		
- 1:75			90		
- 1:100			88		
- 1:1000			54		

*1 g PJ powder was mixed with 2 ml and with 4 ml buffer

Testing of Trypsin Inhibitors from Soybeans

[0072]

STI-A: STI-type I-S Sigma T 9003

STI-B: STI-type II-S Sigman T 9128

STI-C: Bowman-Birke Inhibitor Sigma T 9777 enzyme concentration was 0.02%, inhibitor concentration (end concentration) was 0.125%.

[0073] Possible interactions of the PJ-inhibitor with the substrate was tested by using different concentrations of azo-casein in the same experiment. No interactions were found:

Table 7

	% Inhibition of elastase (0.02%)- activity	
	1% azocasein	2% azocasein
PJ diluted:		
- 1:50	100	100
- 1:100	97	95
- 1:500	87	75
- 1:1000	65	66
- 1:2000	44	51

Skin tests

- [0074] After removing the pads and the cambric the skin was carefully cleaned with tap water and judged immediately and after 1-18 h. No reaction was seen with sterilized faeces (2) nor with STI in buffer (4), however moderate redness, papulas and some vesiculas could be observed at location 1 (faecal supernatant). Location 3 (faecal supernatant with STI) showed a slight redness that disappeared within 60 min.
- [0075] The effect of potato juice or inhibitors derived thereof was also tested in vitro and in a skin test. The results are shown in Figures 1-6. It is possible to inactivate 90-100% of total proteolytic activity, extracts from potato, such as potato juice or inhibitors derived thereof are able to inactivate faecal proteases and this prevents inflammation.
- [0076] In the skin test, PJ was shown to be very effective when applied to treat and prevent an inflammation. Whereas as sterilized faecal supernatant from an ileostomy patient caused an inflammation of the skin, and a severe dermatitis (redness, oedema, vesiculas, pain) when proteolytic enzymes were added, no inflammation was found when potato juice inhibitor was added in both cases. For example ointments, such as creme or gels, when mixed with PJ inhibitor, are capable to inhibit or prevent the local dermatitis.
- [0077] Furthermore, no allergic or other adverse reactions were observed against the potato juice product.

Discussion

- [0078] These experiments show that patients with intestinal inflammations and/or resections of ileum or colon have an increased faecal proteolytic activity. These enzymes impair the protective intestinal mucuslayer as well as the skin in the perineal zone.
- [0079] Crude PJ inhibits the activity of faecal proteolytic enzymes, which hydrolyze azocasein. Purified pancreatic enzymes, trypsin, chymotrypsin and elastase are also inhibited by PJ.
- [0080] It is probably not wise to use faecal supernatans again (for reasons of safety), but a mixture of the 3 purified enzymes in appropriate concentrations has the same effect. Azocasein is a substrate which is hydrolysed by several hydrolytic enzymes, but also enzyme specific substrates can be tested. STI is just one of the inhibitors from soybeans, inhibiting trypsin and chymotrypsin, but not elastase.

FIGURES

[0081]

Figure 1: Inhibition of faecal proteolytic activity by products from potato juice.

Faeces from 1 patient with a well functioning pouch was used.

Faeces was used undiluted.

EURO's were used as 1:5, 1:10, 1:25, 1:50 and 1:100 dilutions in phosphate buffer pH 7.6.

Faeces and EURO were mixed 1:1 for 10 minutes, then the mixture was diluted in phosphate buffer pH 7.6 1:12.5.

In both dilutions proteolytic activity was measured with azocaseine as substrate.

Figure 2: Inhibition of faecal proteolytic activity by products from potato juice

Faeces from 1 patient with an ileostomy was used.

Faeces were used undiluted.

EURO's were used as 1:5, 1:10, 1:25, 1:50 and 1:100 dilutions in phosphate buffer pH 7.6.

Faeces and EURO were mixed 1:1 for 10 minutes, then the mixture was diluted in phosphate buffer pH 7.6 1:12.5.

In both dilutions activity was measured with azocaseine as substrate.

Figure 3: Inhibition of faecal proteolytic activity by products from potato juice

Faeces from 1 patient 14 days after colectomy was used.

Faeces were used undiluted.

EURO's were used as 1:5, 1:10, 1:25, 1:50 and 1:100 dilutions in phosphate buffer pH 7.6.

Faeces and EURO were mixed 1:1 for 10 minutes, then the mixture was diluted in phosphate buffer pH 7.6 1:12.5.

In both dilutions proteolytic activity was measured with azocaseine as substrate.

Figure 4 and Figure 5: Inhibition of faecal proteolytic activity by products from potato juice

Faeces from 2 babies aged 4 months were used.

EP 0 958 833 A1

Faeces were used diluted 1:1 in phosphate buffer pH 7.6 and centrifuged 10 minutes at 10,000 g.

EURO's were used as 1:5, 1:10, 1:25, 1:50 and 1:100 dilutions in phosphate buffer pH 7.6.

Faeces and EURO were mixed 1:1 for 10 minutes, then the mixture was diluted in phosphate buffer pH 7.6 1:12.5.

5 In both dilutions proteolytic activity was measured with azocaseine as substrate.

Figure 6: Patch Test Chambers (van der Bend) of 10 by 10 mm, filled with 50 µl of a test solution were placed on the skin of the upper part of the back of 2 healthy subjects and fixed with Fixomull Stretch self adhesive tape; the distance between them was 15 mm. One series of 4 testchambers was placed from cranial to caudal, a second series from caudal to cranial.

The test solutions had the following composition:

- A. elastase, trypsin and α -chymotrypsin, end concentration of each of the enzymes 1% (Enzyme Mix) soluted in sterilized faecal supernatant from an ileostomy patient (FS)
- 15 B. FS
- C. Euro 2 (end concentration 5%) soluted in FS with Enzyme Mix
- D. Euro 2 in FS

[0082] After 24 hours the test chambers were removed and the skin was rinsed with tap water. Sites were inspected for erythema and dermatitis after 1, 2, 4, 6 and 24 hours.

Claims

1. Use of an inhibitor capable of inhibiting proteolytic activity for preparing a pharmaceutical composition for reducing or preventing an inflammation.
2. Use according to claim 1 wherein said inflammation is an intestinal, perineal, peri-anal or peristomal inflammation.
3. Use of an inhibitor capable of inhibiting proteolytic activity for preparing a personal care composition for peri-anal and/or peri-stomal care.
4. Use of an inhibitor capable of inhibiting proteolytic activity for preparing a diaper.
5. Use according to anyone of claims 1 to 4 wherein said proteolytic activity is faecal.
6. Use according to any one of claims 1 to 4 wherein said inhibitor is derived from a plant, preferably wherein said plant can give rise to fruit, seed, tubers or roots.
7. Use according to claim 6 wherein said plant is a potato plant.
8. Use according to any of claims 1 to 4 wherein said inhibitor is capable of inhibiting a protease which is selected from the group of pancreatic and granulocyte proteases.
9. Use according to claim 8, wherein said inhibitor is at least capable of inhibiting papain and/or pronase.
10. A personal care composition for perineal and/or peristomal care or a diaper comprising an inhibitor of proteolytic activity.
11. A method for reducing or preventing an inflammation comprising subjecting a mammal to a treatment with at least one inhibitor which is capable of inhibiting proteolytic activity of a protease.
12. A method according to claim 11 wherein said mammal is a human being.
13. A method according to claim 11 or 12 wherein said inflammation is an intestinal, perineal, peri-anal or peristomal inflammation.
14. A method according to any of claims 11 to 13 wherein said proteolytic activity is of faecal origin.

15. A method according to any of claims 11 to 14 wherein said inhibitor is derived from a plant.
16. A method according to claim 15 wherein said plant can give rise to fruit, seed, tubers or roots.
- 5 17. A method according to claim 16 wherein said plant is a potato plant.
18. A protease inhibitor for use in a method according to anyone of claims 11 to 17.
19. A plant product comprising protease inhibiting activity for use in a method according to anyone of claims 11 to 17.
- 10 20. A plant product according to claim 19 wherein said plant is potato juice, and/or wherein said product comprises potato juice or an inhibitor derived thereof.
21. A personal care composition or diaper comprising a plant product according to claims 19 or 20.
- 15 22. A skin test for studying the effect of an inhibitor of proteolytic activity on inflammatory action of a substance, preferably of faeces, comprising sterilizing faeces and adding at least one proteolytic enzyme to said sterilized faeces, further comprising placing a sample of said faeces to the skin of a healthy subject.
- 20 23. A skin test according to claim 22 wherein said faeces is derived from an infant or a patient.

25

30

35

40


45

50

55


	Euro 1	Euro 2	Euro 3
10%	35.7	27.4	7.5
5%	55.2	40.9	12.3
2%	83.5	67.7	26.3
1%	100.8	80.8	40.3
0.50%	114.1	92.4	64
0%	131.2	129.9	144.7

**Fig 1a. Effect of EURO on faecal proteolytic activity.
Patient with pouch (F)**




	Euro 1	Euro 2	Euro 3
10%	73	79	95
5%	58	69	92
2%	36	48	82
1%	23	38	72
0.50%	13	29	56


**Fig 1b. Effect of EURO on faecal proteolytic activity.
Patient with pouch (F)**



	Euro 1	Euro 2	Euro 3
10%	15.9	6	2.7
5%	22	12.9	4.5
2%	39	26.8	8.7
1%	49.9	42	14.2
0.50%	87.7	63.8	22.6
0%	105.4	108.5	110.9




	Euro 1	Euro 2	Euro 3
10%	85	94	98
5%	79	88	96
2%	63	75	92
1%	53	61	87
0.50%	17	41	80




	Euro 1	Euro 2	Euro 3
10%	4.6	1.6	0
5%	5.8	2.9	0
2%	8.4	6.1	1.3
1%	12.5	10.1	2.7
0.50%	13.4	15.1	4.7
0%	42	40.6	29.2

Fig 3a. Effect of EURO on faecal proteolytic activity.
Patient (R) with I.A.A. (Two weeks after operation).




	Euro 1	Euro 2	Euro 3
10%	89	96	100
5%	86	93	100
2%	80	85	96
1%	70	75	91
0.50%	68	63	84

Fig 3b. Effect of EURO on faecal proteolytic activity.
Patient (R) with I.A.A. (Two weeks after operation).




	Euro 1	Euro 2	Euro 3
10%	20.1	23.7	10.5
5%	32.3	42.7	14.5
2%	61.7	52.6	19.9
1%	104.6	83.3	25.2
0.50%	135.6	122.9	34.3
0%	170.3	170.3	171.8

**Fig 4a. Effect of EURO on faecal proteolytic activity.
Baby 1 (4 months).**




	Euro 1	Euro 2	Euro 3
10%	88	86	94
5%	81	75	92
2%	64	69	88
1%	39	51	85
0.50%	20	28	80

**Fig 4b. Effect of EURO on faecal proteolytic activity.
Baby 1 (4 months).**



	Euro 1	Euro 2	Euro 3
10%	10.2	0	3.1
5%	13	10.5	5.2
2%	19.4	18.6	7.2
1%	27.5	27.2	10.7
0.50%	53.1	43.2	12.8
0%	123.1	135.1	123.1

**Fig 5a. Effect of EURO on faecal proteolytic activity.
Baby 14 (4 months).**



	Euro 1	Euro 2	Euro 3
10%	92	100	97
5%	89	92	96
2%	84	86	94
1%	78	80	91
0.50%	57	68	90

**Fig 5b. Effect of EURO on faecal proteolytic activity.
Baby 14 (4 months).**






Fig. 6



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	WO 97 04792 A (UNIV PENNSYLVANIA) 13 February 1997 * page 1, line 9 - line 16 * * page 5, line 8 - line 17 *	1, 2, 5, 6, 8, 11-16, 18, 19, 21	A61K38/55 A61K38/56 A61L15/44 G01N33/50
X	DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US Abstract No. 127:126636, YAHAGI, ICHIRO ET AL: "Manufacture of soybean extracts containing trypsin inhibitors for controlling skin disorders" XP002081958 * abstract * & JP 09 176033 A (HEISEI) 8 July 1997 -/--	1-3, 5, 6, 8, 10-16, 18, 19, 21-23	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			A61L A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claim(s) 11-17 are directed to a diagnostic method practised on the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		23 October 1998	Sitch, W
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons B : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C07)



**European Patent
Office**

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 98 20 1694

EPO FORM 1503 03.02 (P04C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 98 20 1694

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (IntCl.8)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	PATENT ABSTRACTS OF JAPAN vol. 018, no. 236 (C-1196), 6 May 1994 & JP 06 025000 A (SUNSTAR INC), 1 February 1994 * abstract *	18, 19	
A	EP 0 564 307 A (LEVI SHALOM ;DAREN STEPHEN (IL)) 6 October 1993 * page 3, line 25 - line 53 *		
A	GB 2 311 727 A (HANSON SHAW BEVERLEY JANE) 8 October 1997 * page 2, line 7 - page 3, line 2 *		
A	BOHE M ET AL: "Protease inhibitors in plasma and faecal extracts from patients with active inflammatory bowel disease." SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, (1986 JUN) 21 (5) 598-604. JOURNAL CODE: UCS. ISSN: 0036-5521., XP002081957 Norway		
			TECHNICAL FIELDS SEARCHED (IntCl.5)